fda glp-1 Pharmacovigilance Assessment of Compounded Receptor Agonists: Insights From the Adverse Event Reporting System Lilly is now pharma's top

But given the strength of the trial data, it's a development worth watching closely

Precision-based assessment before and during treatment may identify responders and non-responders earlier

Moreover, dual GLP-1 and Gcg receptor agonist, dual GLP-1/GIP receptor agonist and GLP-1/GIP/Gcg receptor triagonist have also been successfully applied in the treatment of AD models

While the first GLP-1 was approved by the FDA more than 20 years ago, to treat Type 2 diabetes, the use of these drugs took off in 2021 when Novo Nordisk received approval for a semaglutide drug to treat obesity, with the brand name Wegovy

Han SH, Safeek R, Ockerman K, Trieu N, Mars P, Klenke A, et al

Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression